Clinical Trials Logo
  1. Home
  2. Placenta Previa
  3. NCT03779451

Vaginal Progesterone Versus 17-Alpha-Hydroxyprogesterone Caproate in Placenta Previa

Placenta Previa Clinical Trial

Official title:
Vaginal Progesterone Versus 17-Alpha-Hydroxyprogesterone Caproate for Prevention of Emergent Cesarean Delivery in Asymptomatic Pregnant Women With Placenta Previa: A Randomized Controlled Study

Clinical Trial Summary

Purpose to evaluate the effects of Vaginal Progesterone versus 17-Alpha-Hydroxyprogesterone Caproate for prevention of Emergent Cesarean Delivery in Asymptomatic Pregnant Women with Placenta Previa

Clinical Trial Description

The study will be a randomized open-label clinical trial conducted at a tertiary university hospital outpatient clinic and some private settings at Aswan governorate, Egypt, between January 2019 and March 2022. The authors will include women who asymptomatic pregnant women with a diagnosed placenta previa at 26-28 weeks gestation. They will be randomized into three groups: group I (vaginal progesterone suppositories ), group II (received an intramuscular dose of 250 mg 17-alpha-Hydroxyprogesterone caproate(17-OHPC) once a week) and group III(control group). In each group, Follow-up visits were performed every week then admission was done at 36 weeks at our university hospital. Scheduled caesarian section was done at completed 37 weeks unless otherwise required. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT03779451
Study type Interventional
Source Aswan University Hospital
Contact hany f sallam, md
Phone 01022336052
Email hany.farouk@aswu.edu.eg
Status Recruiting
Phase N/A
Start date January 1, 2019
Completion date April 1, 2022
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT04518150 - Combined Bilateral Uterine Artery Ligation and Bakri Balloon During Cesarean Section N/A
Recruiting NCT04518163 - Bakri Balloon Plus Tranexamic Acid During Cesarean Delivery for Placenta Previa N/A
Recruiting NCT03638024 - Cell-free Fetal DNA Concentration in Cases of Abnormal Placental Invasion .
Terminated NCT01996345 - Vaginal Pessary Versus Expectant Management for Placenta Previa N/A
Recruiting NCT04609527 - Management of Placenta Accreta Spectrum Phase 2/Phase 3
Completed NCT03321435 - The Placenta Previa and Fetal Weight N/A
Completed NCT03431116 - Low Implanted Second Trimester Placenta and Placenta Previa N/A
Enrolling by invitation NCT05529381 - Anxiety and Depressive Symptoms in Placenta Previa / Accreta
Completed NCT04264234 - Management Of Placenta Previa Cases And Determination Of Hospitalization Criteria N/A
Completed NCT05340205 - Blood Loss During Cesarean Delivery in Placenta Previa Patients Phase 4
Completed NCT03570723 - Glove-loaded Foley's Catheter Tamponade for Cesarean Section for Placenta Previa N/A
Completed NCT05283122 - Mostafa Maged Technique to Control and Prevent the Post-Partum Bleeding From the Lower Uterine Segment in Placenta Previa Cases N/A
Withdrawn NCT01442207 - Cerclage for Prevention on Preterm Birth in Women With Placenta Previa Phase 3
Not yet recruiting NCT03451136 - Cervical Length in Cases of Placenta Previa N/A
Completed NCT02966197 - Efficacy of Prophylactic Internal Iliac Artery Balloon Catheterization in the Management of Placenta Previa and Accreta N/A
Recruiting NCT02590484 - The Cervix as a Natural Tamponade in Postpartum Hemorrhage Caused by Placenta Previa and Placenta Previa Accreta N/A
Recruiting NCT05802251 - Sonographic Parameters and Risk of Antepartum Hemorrhage in Asymptomatic Women With Placenta Previa: A Cohort Study
Completed NCT03542552 - Nifedipine Versus Magnesium Sulfate for Prevention of Preterm Labor in Symptomatic Placenta Previa Phase 3
Recruiting NCT03124472 - Effect of Uterine Artery Ligation Prior to Uterine Incision in Women With Placenta Previa N/A
Recruiting NCT03633175 - Progesterone in Patients With Placenta Previa Phase 2